Chinese Herbal Medicines最新文献

{"title":"Prediction of therapeutic targets and drug candidates for pancreatic ductal adenocarcinoma by network-based computational framework","authors":"Jinyuan Lu, Weishan Liang, Yixue Liang, Jiajia Ren, Chengyang Guo, Xia Li, Jianquan Pan, Weidong Zhang, Saisai Tian","doi":"10.1016/j.chmed.2026.03.006","DOIUrl":"10.1016/j.chmed.2026.03.006","url":null,"abstract":"<div><h3>Objective</h3><div>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and an urgent need for novel treatment strategies. This study presented a network-based computational framework for <em>in silico</em> genome-wide therapeutic target identification and drug discovery.</div></div><div><h3>Methods</h3><div>A network-based computational framework was developed that integrates transcriptomic data from multiple independent PDAC cohorts to construct gene co-expression networks. Prognostic gene signatures were incorporated to identify feature modules via hypergeometric enrichment analysis. Key regulatory genes within these modules were prioritized using multi-metric centrality analysis. Functional relevance of candidate targets was assessed using single-cell ribonucleic acid (RNA) sequencing, genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) dependency datasets, and clinical survival analyses. To enable therapeutic translation, this study implemented a transcriptome-guided drug discovery strategy to systematically match pancreatic ductal adenocarcinoma (PDAC)-specific gene expression signatures with compound-induced transcriptional profiles from the Library of Integrated Network-based Cellular Signatures (LINCS) database. Candidate compounds were ranked using a cross-cohort consensus scoring approach and subsequently evaluated <em>in vitro</em> using quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting, and cell viability assays.</div></div><div><h3>Results</h3><div>Comprehensive analysis of multi-cohort PDAC transcriptomic data identified 14 key genes with high network centrality, including three potential oncogenic drivers: Cytoskeleton associated protein 2 like (<em>CKAP2L</em>), kinesin family member 18A (<em>KIF18A</em>), and minichromosome maintenance 10 replication initiation factor (<em>MCM10</em>), which exhibited tumor-specific overexpression and poor prognostic associations. Single-cell RNA sequencing (ScRNA-seq) revealed their predominant expression in epithelial tumor cells, while CRISPR screening confirmed functional essentiality. The transcriptome-guided drug discovery approach matched these targets with LINCS perturbation profiles, identifying mitoxantrone/OTSSP167 (<em>CKAP2L</em> inhibitors), PF-3758309 (<em>KIF18A</em> inhibitors), and vorinostat (<em>MCM10</em> inhibitors) as candidate therapeutics. Experimental validation using qRT-PCR, Western blotting, and cell counting kit-8 (CCK-8) assays collectively demonstrated the dose-dependent therapeutic effects of these compounds, showing significant mRNA suppression, corresponding decreases in protein levels, and potent anti-proliferative activity in PDAC cells.</div></div><div><h3>Conclusion</h3><div>This study establishes a robust, network-based framework for therapeutic target discovery and transcriptome-driven drug prediction in PDAC. It iden","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 835-851"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generative models in traditional Chinese medicine: Advances and applications","authors":"Dezhi Sun,&nbsp;Cheng Zhang,&nbsp;Guangsen Li,&nbsp;Yangyi Hu,&nbsp;Shuman Li,&nbsp;Wei Zhou,&nbsp;Yue Gao","doi":"10.1016/j.chmed.2026.08.013","DOIUrl":"10.1016/j.chmed.2026.08.013","url":null,"abstract":"<div><div>Generative artificial intelligence is increasingly being applied across interdisciplinary fields, enabling cross-modal content generation—spanning text, images, and molecular structures—through self-supervised learning. Confronting persistent challenges in Traditional Chinese Medicine (TCM), such as compositional complexity, ambiguous mechanisms, and unstructured knowledge systems, generative models may provide useful approaches by bridging fragmented data sources and offering scalable tools for prescription generation, molecular design, and knowledge discovery. In practice, large language models (LLMs) convert classical texts and electronic records into structured knowledge for syndrome-aware prescription generation, while fragment-aware GPT-based chemical language models expand natural-product chemical space. This review systematically explores core paradigms and recent advances in applying generative models to TCM research, focusing on key domains including TCM knowledge Q&amp;A, prescription generation, and molecular design. We further critically analyze methodological and ethical challenges while outlining future directions in the field, such as interpretable generative models, integration with TCM knowledge graphs, and novel multimodal training strategies.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 778-788"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted enrichment of bruceine D from Brucea javanica by molecularly imprinted nanomagnetic sorbents","authors":"Qilei Chen,&nbsp;Yueming Huang,&nbsp;Tsz Ching Wong,&nbsp;Guanhua Huang,&nbsp;Yizhao Yang,&nbsp;Jianye Zhang,&nbsp;Hubiao Chen","doi":"10.1016/j.chmed.2025.07.001","DOIUrl":"10.1016/j.chmed.2025.07.001","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to develop and validate a novel method for targeted enrichment of bruceine compounds, whose structural complexity hinders both synthesis and conventional natural extraction. As a case study, bruceine D, a major antitumor component from <em>Brucea javanica</em> (Yadanzi in Chinese), was selected for enrichment using magnetic nanoparticles (MNPs) functionalized with molecularly imprinted polymers (MIPs).</div></div><div><h3>Methods</h3><div>A comprehensive chemical profiling of the <em>B. javanica</em> extract was performed to identify bruceine D and its structural analogues. MNPs coated with bruceine D-MIPs (MMIPs) were synthesized and characterized using various techniques, including transmission electron microscopy to observe the morphology, scanning electron microscopy to analyze the surface structure, and Fourier-transform infrared spectroscopy to confirm the successful functionalization of MIPs on MNPs. The adsorption performance of MMIPs was assessed through static and dynamic adsorption experiments. Subsequently, the process was validated for selectivity, repeatability, and reusability. The adsorption data were modeled using the Freundlich isotherm and kinetic models to reveal the adsorption mechanism.</div></div><div><h3>Results</h3><div>Among multiple analogues, bruceine D was confirmed as a major constituent of the <em>B. javanica</em> extract. The MMIPs demonstrated superior morphology, crystallinity, and functional surface modification, leading to favorable adsorption characteristics. Compared to non-imprinted polymers, they exhibited significantly stronger adsorption intensity and selectivity for bruceine D due to a lower Freundlich isotherm constant (0.0418) and a higher imprinting factor (1.69). The MMIPs showed excellent repeatability with a low relative standard deviation (0.75%) and maintained high extraction efficacy across multiple cycles. The MMIPs successfully isolated bruceine D from <em>B. javanica</em> extract, achieving a remarkable recovery yield (39.50 µg/g).</div></div><div><h3>Conclusion</h3><div>This study demonstrated a novel application of molecular imprinting technology targeting bruceine compounds. In particular, the MMIP-based selective enrichment of bruceine D from <em>B. javanica</em> showed superior efficiency, selectivity, and adsorption capacity compared to conventional methods. This advancement holds significant implications for natural product isolation, offering a sustainable and green strategy in the pharmaceutical industry for the isolation of complex bioactive compounds for therapeutic use.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 1067-1078"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147332736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frankincense from Boswellia: A review of species, traditional uses, phytochemistry, pharmacology and toxicology","authors":"Xiuting Sun,&nbsp;Yujia Yang,&nbsp;Chuhang Peng,&nbsp;Qing Huang,&nbsp;Jianhe Wei,&nbsp;Xinquan Yang","doi":"10.1016/j.chmed.2025.09.007","DOIUrl":"10.1016/j.chmed.2025.09.007","url":null,"abstract":"<div><div>Frankincense, an oleogum resin from <em>Boswellia</em> species, has long been used in traditional medicine and rituals. However, unclear taxonomy, overharvesting, quality variation, and limited pharmacological insight hinder its sustainable use and scientific development. The aim of this review is to summarize the species, distribution, and current resource status of <em>Boswellia</em> plants as well as the formation process, harvesting, traditional uses, phytochemistry, pharmacology and toxicity of frankincense. It also discusses future research trends and development prospects for frankincense, providing guidance for further exploration and utilization. To achieve this, relevant information was systematically gathered from authoritative sources, including ancient books, doctoral and master’s dissertations, the <em>Pharmacopoeia of the People’s Republic of China</em>, Web of Science, PubMed, CNKI, Springer Link, Science Direct, Google Scholar, and Baidu Scholar. The genus <em>Boswellia</em> comprises approximately 24 known species, which produce frankincense, a highly aromatic resin widely used in traditional practices across Arabia, India, China, and Kenya. The <em>Pharmacopoeia of the People’s Republic of China</em> notes the ability of frankincense to promote blood circulation, relieve pain, reduce swelling, and resolve stasis. Over 200 compounds have been identified and isolated from frankincense. Pharmacological studies have demonstrated that frankincense has antimicrobial, anti-inflammatory, anticancer, antiulcer, analgesic, antioxidant, hepatoprotective and neuroprotective effects, with no significant reported side effects or toxicity. However, owing to human activities and environmental degradation, <em>Boswellia</em> resources have become scarce. Some <em>Boswellia</em> species are now endangered, and current research is limited to only a few species, which restricts the development and utilization of frankincense. In summary, frankincense has a long history of medicinal use because of its complex chemical composition and diverse pharmacological activities. Therefore, a comprehensive scientific investigation is needed to ensure the sustainable utilization of frankincense resources, determine the material basis and mechanisms underlying its traditional uses, explore its potential applications in new fields, and increase its utilization.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 960-982"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HXZQCG: A database of natural diverse components in polyherbal formulation HXZQ identified naringenin chalcone as a ligand of H2R","authors":"Shengjie You,&nbsp;Jing Mo,&nbsp;Guoqing Xu,&nbsp;Zhuangyuan Xie,&nbsp;Wenke Xiao,&nbsp;Guiyang Zhang,&nbsp;Yufei Mao,&nbsp;Qi Shen,&nbsp;Leu Kim Fey,&nbsp;Sanyin Zhang,&nbsp;Wei Chen,&nbsp;Liang Leng,&nbsp;Fanbo Meng","doi":"10.1016/j.chmed.2026.06.003","DOIUrl":"10.1016/j.chmed.2026.06.003","url":null,"abstract":"<div><div>Huoxiang Zhengqi (HXZQ) is a classical polyherbal formulation used to treat gastrointestinal disorders. It exerts multi-targeted therapeutic effects, yet its phytochemical complexity hinders standardization and modern pharmacological development. This challenge is further exacerbated by the lack of comprehensive resources covering its diverse natural components, particularly as most previous research neglected peptides and small RNAs, which possess emerging therapeutic potential. There is an urgent need for novel research models to explore polyherbal formulations such as HXZQ. Here, we present the Huoxiang Zhengqi Component Galaxy (HXZQCG), a dedicated database for the HXZQ. HXZQCG integrates over seven million natural components through artificial intelligence-assisted mining, including 15 811 metabolites, 7 597 212 small peptides, and 152 342 small RNAs. To demonstrate its utility, we applied HXZQCG to screen for ligands of the histamine H₂ receptor (H₂R), a well-established and druggable G Protein-Coupled Receptor (GPCR) target widely implicated in gastrointestinal pathologies. Through high-throughput screening of potential ligands for H₂R based on the HXZQCG, we identified 125 candidates. Candidates identified through virtual screening were validated via cell membrane chromatography, ultimately identifying two putative binding small molecules. Furthermore, our results demonstrated that naringenin chalcone is a ligand of H₂R, and it can inhibit the downstream accumulation of cyclic adenosine monophosphate (cAMP). In sum, HXZQCG stands as a representative case study for polyherbal formulation research. It provides data-based resources for discovery of active component and elucidation of pharmacological mechanisms, serving as a fundamental data-driven platform to support the secondary development of HXZQ. HXZQCG is available at https://cbcb.cdutcm.edu.cn/HXZQCG/.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 807-819"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148305513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut-liver axis and intestinal microbiota: Key targets of herbal medicines in treatment of MASLD/MASH","authors":"Yiqin Mao,&nbsp;Caihong Wei,&nbsp;Yi Zhang,&nbsp;Yiqin Zheng,&nbsp;Ruifeng Ji,&nbsp;Ge Lin,&nbsp;Xin He,&nbsp;Yisheng He,&nbsp;Ji Yang,&nbsp;Jiang Ma","doi":"10.1016/j.chmed.2026.08.017","DOIUrl":"10.1016/j.chmed.2026.08.017","url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) represent globally prevalent chronic hepatic conditions, in which gut dysbiosis acts as a key pathogenic driver through dysregulation of the gut-liver axis. Herbal medicines (HMs) are increasingly recognized as viable therapeutic candidates for MASLD/MASH, primarily through their ameliorative properties on gut-liver axis and pathophysiological pathways of intestinal microbiota. This review summarizes the pathogenesis of MASLD/MASH and the application of HMs in their treatment from the perspective of the gut-liver axis and intestinal microbiota. The progression of MASLD/MASH involves several pathological processes marked by modifications in the gut-liver axis, including compromised gut barrier function and increased intestinal permeability causing endotoxemia and inflammation, along with alterations in microbiota composition and gut microbiota-derived metabolites. This review further delineates the shared mechanisms within each class of compounds in HMs for ameliorating MASLD/MASH, highlights recent advances in the combined use of HMs and probiotics, and discusses the key issues and challenges associated with the clinical translation of HM-based preparations. These insights potentially catalyze the advancement of novel therapeutics targeting MASLD/MASH, while providing a translational framework for clinical application of HMs.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 939-959"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic characterization of AP2/ERF transcription factors related to cannabinoids biosynthesis in Cannabis sativa","authors":"Wei Yao,&nbsp;Lirong Su,&nbsp;Zhimei Lu,&nbsp;Jitong Chen,&nbsp;Lixin Duan,&nbsp;Xiangxiao Meng,&nbsp;Huihua Wan,&nbsp;Shilin Chen,&nbsp;Yaolei Mi,&nbsp;Aijia Ji","doi":"10.1016/j.chmed.2025.06.001","DOIUrl":"10.1016/j.chmed.2025.06.001","url":null,"abstract":"<div><h3>Objective</h3><div>Cannabinoids, secondary metabolites produced by <em>Cannabis sativa</em> (cannabis), have various pharmacological effects, such as anti-inflammatory and analgesic effects, and they can be used in the treatment of Alzheimer’s disease. Although the biosynthetic pathway of cannabinoids has been elucidated, relatively few reports about the transcription factors involved in this pathway exist. APETALA2 (AP2)/ethylene-responsive factor (ERF) transcription factor (TF) families play an important role in plant growth and secondary metabolism.</div></div><div><h3>Methods</h3><div>APETALA2 (AP2)/ethylene-responsive factor (ERF) transcription factor (TF) family was identified in cannabis plants via phylogenetic analysis, chromosomal distribution, gene structure, conserved motif identification, synteny analysis, alternative splicing event identification, response element prediction, and gene expression analysis.</div></div><div><h3>Results</h3><div>A total of 111 AP2/ERF members belonging to the APETALA2 subfamily (17 genes), dehydration-responsive element-binding proteins subfamily (39 genes), and ethylene-responsive factor subfamily (53 genes), related to the ABI3/VP1 subfamily (two genes), exist in cannabis. Based on the expression profiles of AP2/ERFs in the genome, quantitative real-time PCR (qRT-PCR) detection and coexpression analysis results, the functional genes of six TFs were clustered with those of other species, and two gene clusters are speculated to be related to cannabinoid biosynthesis. A total of six CsERF proteins were found to be located in the cell nucleus by subcellular localization detection. CsERF02 and CsERF19 exhibited transcriptional activation activity through the AH109 yeast system.</div></div><div><h3>Conclusion</h3><div>CsERF02, CsERF05, CsERF18, CsERF19, CsERF21, CsERF46 and two gene clusters may function in cannabinoid biosynthesis. These results contribute to the characterization of functional AP2/ERF family members in cannabis and lay a foundation for regulating cannabinoid content through metabolic pathways.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 1056-1066"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of four new coumarins from Zanthoxylum avicennae and transcriptomic elucidation of avicennol-mediated protection against NAFLD through CD36 and IL-1β regulation","authors":"Syed Shams ul Hassan,&nbsp;Chuyin Ou,&nbsp;Xue Xiao,&nbsp;Jiajia Wu,&nbsp;Mingyu Ma,&nbsp;Lina Wang,&nbsp;Yan Ji,&nbsp;Huizi Jin,&nbsp;Shikai Yan","doi":"10.1016/j.chmed.2026.08.012","DOIUrl":"10.1016/j.chmed.2026.08.012","url":null,"abstract":"","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 1079-1081"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-based strategies for diagnosis and therapeutic discovery in pulmonary fibrosis","authors":"Yue Lin,&nbsp;Qianqian Liu,&nbsp;Xiangyi Lei,&nbsp;Huiyu Cao,&nbsp;Pengmian Feng,&nbsp;Yuemei Wang,&nbsp;Dan Sun,&nbsp;Guang Xin,&nbsp;Sanyin Zhang,&nbsp;Wei Chen","doi":"10.1016/j.chmed.2026.08.005","DOIUrl":"10.1016/j.chmed.2026.08.005","url":null,"abstract":"<div><div>Pulmonary fibrosis (PF) is a life-threatening and therapeutically challenging disease, underscoring the urgent need for novel and effective interventions. Natural products, characterized by structural diversity, wide biological activities, and abundant availability, represent a promising reservoir for anti-fibrotic drug discovery. This review provides a comprehensive overview of the key risk factors and complex pathogenic mechanisms underlying PF, with a particular focus on the pro-fibrotic and anti-fibrotic targets that regulate disease progression. Special attention is given to high-value candidate targets identified through data-driven approaches, including members of the G protein-coupled receptor (GPCR) family. This study further summarizes the emerging roles of artificial intelligence (AI) in PF diagnosis and prognostic assessment, where deep learning models significantly enhance imaging interpretation and patient stratification. In addition, the anti-fibrotic mechanisms of natural products are systematically discussed, especially their modulation of fibroblast-to-myofibroblast transition (FMT), epithelial-mesenchymal transition (EMT), and endothelial-to-mesenchymal transition (EndMT). Building on these insights, this study proposes an AI-driven workflow for natural product-based anti-fibrotic drug discovery, integrating target identification, virtual screening, and experimental validation. This integrative strategy offers a conceptual and technical framework for accelerating the development of natural-product-derived therapeutics for PF.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 789-806"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of PDE4D as a common molecular target of five bufadienolides from Liushen Pill in experimental acute pharyngitis","authors":"Xinyi Tang,&nbsp;Weiguo Chen,&nbsp;Hui Gong,&nbsp;Jing Zhou,&nbsp;Yuyu Zhu,&nbsp;Wenyuan Wu,&nbsp;Meixin Tian,&nbsp;Xiaoyang Hu,&nbsp;Haibo Cheng,&nbsp;Jinao Duan,&nbsp;Hongyue Ma","doi":"10.1016/j.chmed.2026.08.014","DOIUrl":"10.1016/j.chmed.2026.08.014","url":null,"abstract":"","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 920-922"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}